Showing posts with label NIMH. Show all posts
Showing posts with label NIMH. Show all posts

July 27, 2008

Chandler's Chelation in the Local News

We were interviewed by a New Hampshire paper that ran two stories today.  One about our experience with chelation and the other about the NIMH Study.

Please note the superhuman cuteness of my baby.

Mother: 'We're not waiting for the government'

By ROBERT M. COOK
bcook@fosters.com
Article Date: Sunday, July 27, 2008
Picture
Courtesy photo Chandler Taylor, 6, of Brunswick, Maine, gets biweekly chelation treatments at the Chelation Medical Center in Gray, Maine, to treat his autism.

Ginger Taylor wasn't sure what she could do to help her son, Chandler, when he first was diagnosed with autism spectrum disorder at age 2.

But after the Brunswick, Maine, woman discovered how much he benefited from chelation therapy, as well as a gluten- and casein-free and special carbohydrate diet, Taylor found the answer to her prayers.

She said her son, now 6, is well on the road to recovery.

Chandler receives biweekly, 15-minute intravenous treatments at the Chelation Medical Center in Gray, Maine, to remove lead, mercury and other toxic metals from his body. The treatments use a fluid containing agents that help remove the metals from the bloodstream. He also receives "Myers" cocktails to restore minerals and vitamins to his system, Taylor said.

The family's health insurance will not cover the procedure, the cocktail or special diet supplements. Taylor said they pay $300 weekly for everything, but the results have been worth it.

Picture
Courtesy photo Scott Taylor of Brunswick, Maine, plays with his son, Chandler, 6. Chandler was diagnosed with Autism Spectrum Disorder at age 2 and his parents said a combination of chelation treatment, a gluten-free and casein-free diet and a special carbohydrate diet have helped him develop better speech and learning skills.

"In the first two weeks he had dramatic improvement, and he started potty training. He has better eye contact, and his words took off," Taylor said. "He went from speaking four-word sentences to four sentences."

She said her son also started playing better with his older brother, Webster, 7, and her neighbor's children, who are the same age as Chandler. With the help of an aide, he also has attended kindergarten in the Brunswick public schools and she is hopeful he'll do well when he attends first grade this fall.

The National Institutes of Mental Health in Bethesda, Md., proposed doing a chelation treatment study earlier this month to determine how it helps children diagnosed with autism. If the study is approved, it would mark the first time the federal government has taken a close look at an alternative treatment for autism.

While Taylor said she's pleased the federal government wants to study the benefits of chelation as an autism treatment, she said the NIMH should have done so long ago.

"Parents have been reporting for years that it has been helping their kids," Taylor said.

She also said the danger associated with chelation has been exaggerated, calling it safe if administered properly by a doctor certified by a chelation board.

"We're not waiting for the government to do anything," she said.

Doctors with Defeat Autism Now!, or DAN, believe children with autism are unable to break down metals such as mercury and lead the same way normal developing children do because their immune systems are compromised.

They believe gluten- and casein-free diets, which don't use wheat and dairy products, and alternative treatments like chelation, can remove toxic metals from children and eventually let them function normally.

Taylor said her son benefited from the diet and chelation almost immediately after he started it in California, where the family lived before moving to Maine in 2006.

She said her son "started calling me mommy again for the first time in 10 months."

Unlike a standard blood test doctors use to detect high levels of lead and mercury, Taylor said a chelation test focuses on urine. In Chandler's case, his first chelation test showed he had high levels of lead and mercury, she said.

She said the family stopped chelation for nearly two years and had his urine tested again for metals after they moved to Maine. The test showed he again had elevated levels of mercury, lead and toxins, she said.

She said she believes her son may have ingested lead from mouthing toys later recalled for having lead paint. She said her son also may have ingested lead paint from the window frames of their Maine home.

She said she's not sure if her son will completely recover from autism, but believes chelation treatments have made a huge difference.

"We are going to keep doing it until all the metals are gone," she said.

New frontiers in autism research

By ROBERT M. COOK
bcook@fosters.com
Article Date: Sunday, July 27, 2008
Picture
Dr. Patrick Mulcahy

Some advocates believe the federal government's willingness to study the benefits of chelation treatments may signal a turning point in the fight against autism.

"It's long past due," said Ginger Taylor of Brunswick, Maine, who has a 6-year-old son diagnosed with autism who has been receiving chelation treatments for more than a year. "Parents have been reporting for years that it has been helping their kids."

The proposed study is one of several recent developments that may shed new light on the causes of the neurological disorder, which affects one of every 150 children, according to the federal Centers for Disease Control and Prevention.

The CDC has said 25,000 children per year are diagnosed with autism spectrum disorders and the U.S. spends $35 billion yearly in federal dollars on related services, ranging from early education programs to adult services.

But advocates are not optimistic researchers at the National Institutes of Mental Health in Bethesda, Md., will end up producing a chelation treatment study of value unless they can approach it the right way.

Dr. Susan Swedo, who heads the federal institute's in-house autism research, is the principal NIHM investigator who wants to do the study, according to Joseph Carey, an NIHM spokesman. He said the study was put on hold for safety concerns after an animal study, published last year, linked DMSA, a chelating agent, to lasting brain problems in rats.

Swedo has proposed recruiting 120 autistic children ages 4 to 10 and giving half DMSA, a chelating agent, and the other half a placebo. The 12-week test would measure before and after blood mercury levels and autism symptoms. The study outline says failing to find a difference between the two groups would contradict reports that chelation works, according to NIHM officials.

Many parents, including Taylor, also have said they're hopeful the Hannah Poling case in March in Georgia will force the federal government to study the relationship between childhood vaccines and autism. Federal health officials conceded that vaccines may have contributed to Poling developing autism.

Poling, a 9-year-old girl, suffers from a condition that affects her mitochondria. Her parents filed a claim with the U.S. Department of Health and Human Services' Vaccines Compensation Program, saying childhood vaccines she received when she was 19 months old triggered her autism.

The government conceded in March that vaccines may have hurt Hannah and has agreed to pay her family for her care.

Advocates long have contended that the mercury preservative thimerosal, which has been used in vaccines, and the policy of administering several vaccinations in one shot to children at age 2 may be the trigger that causes children with a genetic predisposition to develop autism.

Nearly 5,000 families are seeking compensation because of autism or other developmental disabilities, citing vaccines and thimerosal, which has been banned by the U.S. Food and Drug Administration since 2001 except in certain flu shots.

Earlier this month, NIMH Director Dr. Thomas Insel said his group has proposed studying chelation, currently used by doctors to treat lead poisoning.

Last year, the National Institutes of Health spent less than 5 percent of its $127 million autism research budget on alternative therapies, Insel said. He said he is hopeful the chelation study will be approved. The federal government now spends a total of $300 million each year on all forms of autism research.

Dr. Patrick Mulcahy, a Kennebunk, Maine, osteopathic physician with the organization Defeat Autism Now!, or DAN, said he's pleased the government wants to do a study.

"Overall, it's showing that the government and organized medicine is starting to validate or question that there is some valid reasoning for doing these types of treatments," Mulcahy said.

DAN formed to raise private funding for autism research, including on alternative therapies such as chelation, citing low federal spending.

Mulcahy does not offer chelation treatments, but does prescribe methyl-B-12 shots every three days to help children with autism rid their bodies of metals. He also prescribes gluten- and casein-free diets.

"I actually think the diet would be more of a fruitful study," he said.

Nationwide, at least three deaths, including one of an autistic child, resulted from improper chelation treatments, according to the CDC.

Meanwhile, researchers continue to find new genetic clues about autism's cause.

Earlier this month, Dr. Christopher Walsh and Dr. Eric Morrow of Harvard University searched for genes and mutations associated with autism in 88 families from the Middle East, Turkey and Pakistan in which cousins married and had children with autism. They studied families in which parents share ancestry because the strategy increases the chance of finding inherited genes.

The researchers reported in the July 11 issue of "Science" that they linked several gene mutations to autism. The largest group of implicated genes are involved in changes in synapses — the areas between neurons in the brain — that underlie learning. Such genes are vital to the developing brain.

"Autism symptoms emerge at an age when the developing brain is refining the connections between neurons in response to a child's experience," Walsh said.

Other NIMH funded research includes the Autism Genetic Resource Exchange, a project initiated by the Cure Autism Now Foundation. Genetic samples are being collected from several hundred families with more than one member who has been diagnosed with autism so scientists can learn more about the genes that hinder brain development.

The Autism Tissue Program has received funding from the Harvard Brain and Tissue Resource Center, the NIMH and the National Institute of Neurological Disorders and Stroke. Researchers can study post-mortem brain tissue with imaging methods.

All of those research projects involve gene-mapping, which has been the federal government's preferred track to understanding autism.

Dr. Stephen Edelson, director of the Autism Research Institute in San Diego, Calif., said the fact that the federal government even wants to study chelation could signify a turning point.

He said doctors with the American Academy of Pediatrics now are having extensive dialogue with DAN! doctors about the benefits of gluten- and casein-free diets and other treatments.

Edelson said potential research breakthroughs will happen when the medical community, federal government and autism advocacy groups come together and pool their resources. He compared such an effort to how Americans worked together at home and abroad to achieve a singular goal to win World War II.

He said he's optimistic continued public pressure from the growing number of parents with children diagnosed with autism will lead to serious studies about the relationship between childhood vaccines and the disorder.

"More is happening, but not enough," Edelson said.

January 16, 2008

It Just Keeps Getting More Absurd

So apparently the woman hired by NIMH to coordinate the attack on the autism epidemic, may not believe that there is an autism epidemic.

The new head of the Interagency Autism Coordinating Committee(IACC)is Joyce Chung, who is the wife of Roy Grinker, who wrote a book and tours the nation, claiming there is no autism epidemic.

I feel like I am taking crazy pills.

So are the bajillions of dollars in CAA money now going to research that proves Grinker's head in the sand theory is true, rather than actually looking for the causes and cures of autism?

A year or so before I became a mom, me and 4 of my friends started a prayer group/bible study type thing. Two of the five of us now have autistic sons. Another has a daughter with severe autoimmune disorder.

When I was in Jr. High my best friends were identical twins that lived next door, two of the three of us have autistic sons. The third has a son with a severe autoimmune disorder.

I am wondering what the stats would be for my groups of girlfriends gone by if I tried to get back in touch with all of them.

But Autism Speaks and now NIMH are propping up proponents of the idea that there is no epidemic.

All I can think of is sarcastic comments to make, so I will just stop here and let Wade, the voice of reason, and JB, the voice of pissed off parents everywhere, take over.

January 3, 2008

NIMH Wants to Know What Direction Autism Research Should Go

... or at least they say they do.

I encourage you to write to them tomorrow and let them know what you would like looked at. Take a moment right now to put your thoughts down to be sure you get it in by the Jan 4th deadline.

From NAA:

Respond to NIMH's Request for Information about Autism Research Priorities


Due Tomorrow, January 4, 2008

Request for Information (RFI): Research Priorities for the Interagency Autism Coordinating Committee Strategic Plan for Autism Spectrum Disorders (ASD)

The purpose of this time-sensitive RFI is to seek input from ASD stakeholders such as individuals with ASD and their families, autism advocates, scientists, health professionals, therapists, educators, state and local programs for ASD, and the public at large about what they consider to be high-priority research questions.

Background
The Combating Autism Act of 2006 (Public Law 109-416) re-established the Interagency Autism Coordinating Committee (IACC) and requires that the IACC develop a strategic plan for ASD research. The IACC includes both Federal and public members who are active in the area of ASD research funding, services, or advocacy. In its inaugural meeting on November 30, 2007, the IACC approved a process for developing the strategic plan that includes multiple opportunities for stakeholder input. This RFI is a first step in receiving broad input at the beginning stages of plan development.

To identify research priorities for possible inclusion in the strategic plan for ASD research, the IACC will convene several scientific workshops in January 2008. The responses received through this RFI will be collated, summarized, and provided to workshop participants. The scientific workshops will be organized around four broad areas of ASD research:

Treatment - includes ASD treatment, intervention, and services research that aim to reduce symptoms, promote development, and improve outcomes. This area includes the development and evaluation of medical, behavioral, educational, and complementary interventions for ASD. In addition, this area includes research studies that evaluate the effectiveness of treatments in real world settings, disparities in ASD treatment among specific subpopulations, practice patterns in ASD programs and services, and their cost-effectiveness.

Diagnosis - is concerned with the accurate and valid description of ASD (phenotype) both at the individual and the population level. The public health impact of ASD can be better understood by such studies. In addition, this area concerns itself with the diversity of what constitutes ASD and the characteristics of the condition over the lifespan.

Risk Factors - has to do with investigations of the factors that contribute to the risk of having an ASD in a given person or population. This includes genetic studies of clusters or sporadic occurrences of ASD, studies that focus on environmental factors, e.g., intrauterine events or exposure to toxins, which could lead to ASD, and the interaction between these factors that concentrate risk for ASD.

Biology -studies the underlying biological processes that lead to developmental and medical problems associated with ASD. This includes research in the area of neurosciences but does not confine itself to neurosciences. Therefore, research on other organ systems, interactions between organ systems, and/or other disease processes are included in this area.

The development of the strategic plan is expected to take approximately six months and will include several additional opportunities for public input.

Information Requested
We are interested in receiving your input and ideas about what are high-priority questions and issues for advancing research on ASD. We ask for your constructive and specific suggestions in the following areas (please refer to the above descriptions for each area).

What topics or issues need to be addressed to advance research on the:

1. Treatment of ASD?
2. Diagnosis of ASD?
3. Risk factors for ASD?
4. Biology of ASD?
5. Other areas of ASD research?

Responses
Please send responses to iacc@mail.nih.gov no later than January 4, 2008.

Please limit your response to two pages and mark it with this RFI identifier NOT-MH-08-103 in the subject line. The responses received through this RFI will be collated, summarized, and provided to scientific workshop participants in January 2008. Summarized results will also be made available to the public. Any proprietary information should be so marked. Respondents will receive an email confirmation acknowledging receipt of their response, but will not receive individualized feedback.

------------- end of NIMH message -------------

The following are suggested topics to cover:

* Highest priority should be on preventing new cases and treating individuals already affected.
* Congress made clear in the Combating Autism Act legislative history that NIH MUST investigate vaccines including preservatives as possible causes.
* A vaccinated vs. unvaccinated population study must be conducted.
* In order to better understand the mechanisms of autism onset, and consistent with new emphasis on early detection and treatment, a specific program should be undertaken, probably inpatient, to study newly diagnosed (suspected) cases of ASD to examine in vivo the specific processes and developmental mechanisms involved during onset.
* Documentation and publication of "recovered" cases.
* Evidence-based validation or rejection of treatments (behavioral and biomedical) currently being used to treat existing cases.

Process issues at NIH regarding autism research

* All workshops and workgroup meetings must be open to interested parties.
* Transparency and frequent opportunities for public input and feedback.
* The urgency of the epidemic demands all deliberate speed.
* Workgroup Chairmen must not have financial conflicts.
* Workgroups and workshops must have balance reflecting the diversity of views on cause and treatments for ASD, and not be biased toward past paradigms.
* The point of the Congressional mandate in the Combating Autism Act was to reprioritize and redirect research funding, not to simply repeat past funding hoping for a different outcome.